Amarantus Bioscience Holdings Inc (AMBS)

[JPetroInc]

LymPro as an LDT

"If successful, LymPro can begin generating revenue as a laboratory developed test ("LDT") within 18 months of study initiation through commercial sales and through sales to companies performing Alzheimer's disease clinical research."

"We are pleased with the reproducibility we have seen with the assay at BD," commented Paul Jorgensen, Head of Diagnostics Product Development at Amarantus. "We evaluated various conditions for assay performance and were able to clearly demonstrate suitable analytical performance that will underpin the validity of the ability of LymPro to differentiate Alzheimer's from non-Alzheimer's using both univariate and multivariate models. We are pleased to be sharing the data, along with a scientific and clinical data summary to support the cell cycle dysregulation hypothesis in Alzheimer's disease."

AMBS expects to present LymPro sensitivity and specificity data at the C4CT UN Conference in NYC this Thur., July 31st, 2014.

AMBS expects to beging LDT sales and generating revenue starting 4Q14

AMBS is expected to provide formal revenue guidance in 3Q14

AMBS is expected to announce LymPro JV Partner by end of summer, 2014